Last reviewed · How we verify
Voriconazole preemptive genotyping strategy
A pharmacogenomic strategy that uses CYP2C19 genotyping to optimize voriconazole dosing and reduce adverse events in individual patients.
A pharmacogenomic strategy that uses CYP2C19 genotyping to optimize voriconazole dosing and reduce adverse events in individual patients. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.
At a glance
| Generic name | Voriconazole preemptive genotyping strategy |
|---|---|
| Sponsor | Instituto de Investigación Hospital Universitario La Paz |
| Drug class | Triazole antifungal with pharmacogenomic optimization |
| Target | CYP2C19 enzyme (pharmacogenomic target); fungal lanosterol 14α-demethylase (therapeutic target) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Voriconazole is a triazole antifungal agent whose metabolism is highly dependent on CYP2C19 enzyme activity, which varies significantly among individuals due to genetic polymorphisms. By preemptively genotyping patients for CYP2C19 variants (poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultra-rapid metabolizers), clinicians can adjust voriconazole dosing to maintain therapeutic drug levels while minimizing toxicity. This personalized medicine approach reduces the risk of subtherapeutic exposure or drug accumulation-related adverse effects.
Approved indications
- Invasive aspergillosis
- Candidemia and other Candida infections
- Esophageal candidiasis
- Scedosporium and Fusarium infections
Common side effects
- Visual disturbances (photopsia, blurred vision)
- Hepatotoxicity (elevated transaminases)
- Rash
- Photosensitivity
- Hallucinations or neuropsychiatric effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: